Oral cancer‐associated tertiary lymphoid structures: gene expression profile and prognostic value
Author(s) -
Li K.,
Guo Q.,
Zhang X.,
Dong X.,
Liu W.,
Zhang A.,
Li Y.,
Yan J.,
Jia G.,
Zheng Z.,
Tang W.,
Pan L.,
An M.,
Zhang B.,
Liu S.,
Fu B.
Publication year - 2020
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1111/cei.13389
Subject(s) - neogenesis , cxcl13 , chemokine , cancer , immune system , gene expression profiling , immunology , gene expression , lymph node , medicine , cancer research , biology , gene , biochemistry , islet , chemokine receptor , insulin
Summary Tertiary lymphoid structure (TLS) provides a local and critical microenvironment for both cellular and humoral immunity and supports effective antigen presentation and lymphocyte activation. However, the gene expression profile and prognostic significance of TLS in oral cancer remain largely unrevealed. In this study, we found the presence of both intratumoral and peritumoral TLSs in a series of 65 patients with oral cancer treated by surgical resection, with positive detection rates of 33.8 and 75.4%, respectively. The presence of intratumoral TLSs, but not peritumoral TLSs, was significantly associated with decreased P53 and Ki67 scores ( P = 0·027 and 0·047, respectively). The survival analyses revealed that oral cancer patients with higher grades of TLSs was associated with improved disease‐free survival (DFS) and overall survival (OS) ( P = 0·037 and 0·031, respectively). Gene expression profiling analysis of the cytokines and chemokines responsible for lymph‐node neogenesis identified a three‐up‐regulated‐gene set, i.e. IL7 , LTB and CXCL13 , which was shown to be correlated with human oral cancer‐associated TLSs. This study provides a framework for better understanding of oral cancer‐associated TLSs and for delineating future innovative prognostic biomarkers and immune therapeutic strategies for oral cancer.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom